USANA Health Sciences (NYSE: USNA) reported Q2 EPS of $0.54, $0.11 worse than the analyst estimate of $0.65. Revenue for the quarter came in at $213 million versus the consensus estimate of $221.01 million.

GUIDANCE:

USANA Health Sciences sees FY2024 EPS of $2.40-$2.55, versus the consensus of $2.77. USANA Health Sciences sees FY2024 revenue of $850-880 million, versus the consensus of $883.5 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.